Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 7/20 | 0.81 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.81 |
| ▸ | PLG | P00747 | 6/20 | 0.76 |
| ▸ | F2 | P00734 | 3/20 | 0.69 |
| ▸ | F10 | P00742 | 3/20 | 0.69 |
| ▸ | F7 | P08709 | 1/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.64 |
| ▸ | PLAT | P00750 | 2/20 | 0.64 |
| ▸ | HPN | P05981 | 1/20 | 0.63 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.63 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517426 | 0.98 | PLAU (0.83) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL14355116 | 0.98 | PLAU (0.83) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL14519390 | 0.97 | PLAU (0.86) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL12348362 | 0.95 | PLAU (0.79) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL14519365 | 0.92 | PLAU (0.73) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL14599555 | 0.91 | PLAU (0.77) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL29464816 | 0.90 | PLAU (0.76) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL5413646 | 0.90 | PLAU (0.76) | PLAUPRSS1PLGF2F10 | |
| SCHEMBL30879664 | 0.90 | PLAU (0.80) | PLAUPRSS1PLGCHEK2 | |
| SCHEMBL14519369 | 0.90 | PLAU (0.74) | PLAUPRSS1PLGF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096441-A1 | TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096441-A1 | TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS | PKD2, PKD1, MUC1 | PLAU 959/4885PRSS1 2689/4885PLG 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.